WIPO: Life Sciences symposium: IP and Bioethics A framework for looking at IP and Bioethics September 2007 A.S.Taubman Global IP Issues Division, WIPO.

Slides:



Advertisements
Similar presentations
Brief overview of TRIPS and development – themes and sectors
Advertisements

Fourth Global Congress on Combating Counterfeiting and Piracy WIPO Development Agenda: a New Global Initiative Dubai February 3 to 5, 2008 Pushpendra Rai.
ACCESS TO GENETIC RESOURCES AND BENEFIT-SHARING UNDER THE CONVENTION ON BIOLOGICAL DIVERSITY RECENT DEVELOPMENTS ON ACCESS TO GENETIC RESOURCES AND BENEFIT-SHARING.
A Human Rights Approach to the Benefits of Scientific Progress Audrey R. Chapman, Ph.D. University of Connecticut School of Medicine July 26, 2010 AAAS.
SOS Interop II Sophia Antipolis, September 20 and 21, 2005 IPRs and standards: some issues Richard Owens Director, Copyright E-Commerce Division Philippe.
ARIPOs Initiative on Traditional knowledge and Access and Benefit Sharing. By F.K MPANJU Patent Examiner (ARIPO) Cape Town 19 th –24 th Nov
4 th Meeting of the EC International Dialogue on Bioethics Copenhagen, June 19 th, 2012 Large research and medical databases in clinical and research multi-centred.
Patent Systems in DCs and LDCs: The Need for Coherence between Patent Law and Public Policies Cairo, 6 May 2013 Mohamed Omar Gad Ministry of Foreign Affairs.
Dubai Conference May 2004 Molengraaff Institute Center for Intellectual Property Law (CIER) 2 OVERVIEW Domain Concepts Methodologies Problematic Issues.
Looking Good: Appeal of Designs in Getting Noticed by the Customer Dr. Kristina Janušauskaitė Advocate (Lithuania) WIPO TOT Program for SMEs Damascus,
Least Developed Countries: IP Needs Assessment: WIPO, WTO and the LDC needs assessment process under TRIPS WIPO Conference on Building Partnerships for.
Access to and Use of Traditional Knowledge A view from industry Bo Hammer Jensen.
Agrobiodiversity and Intellectual Property Rights: Selected Issues under the FAO International Treaty on Plant Genetic Resources for Food and Agriculture.
POLICY IMPLICATIONS OF NEW TRENDS IN TECHNOLOGY TRANSFER John H. Barton
Synergies between IP governance and South –South Cooperation on IP and Development First WIPO Interregional Meeting on South-South Cooperation on IP Governance;
Tri-Council Policy Statement 2010 Ethical Conduct for Research Involving Humans.
William Campbell, Tribal-State Environmental Liaison Inter-Tribal Council of Nevada Sparks, NV
National Intellectual Property Strategies, Some Examples and Their Significance June, 2005 Maputo, Mozambique WIPO Intellectual Property and New Technologies.
Interface between patent and sui generis systems of protection of plant varieties The 1978 UPOV Act does not allow both systems to be applied to the same.
Convention on Biological Diversity, Traditional Knowledge and the TRIPS Agreement Yovana Reyes Tagle University of Helsinki.
Developing National Legislation based on the Pacific Model Law 2002 “Empowering Local Communities: Protection of Indigenous Rights” Knowledge Economy Fostering.
Access and Benefit Sharing and the Nagoya Protocol Nashina Shariff Manager Environmental Stewardship Branch November 2014.
Intellectual Property Strategies For Development: Issues and Challenges WIPO Second Annual Conference on South-South Cooperation on Intellectual Property.
Exception to rules on free trade Need to strike a balance between free trade and other values. Member can justify measures incompatible with WTO Agreements.
Intellectual Property in the Context of Growth and Development of the World Economy Luciano Daffarra, Attorney at Law Daffarra, d’Addio & Partners China-Italy.
The WIPO Development Agenda: An Overview Geneva May, 2009 Esteban Burrone World Intellectual Property Organization.
The Relationship between TRIPS and the Convention on Biological Diversity (CBD) - State of play in the TRIPS Council - WTO Symposium on Trade and Sustainable.
Potential trade implications of CBD and the Cartagena Protocol on Biosafety MEA – UNEP meeting on Enhancing MEA and WTO Information Exchange 11 November,
Convention on the Protection and Promotion of the Diversity of Cultural Expressions Adopted 20 October 2005 Entry into force 18 March 2007.
UNCTAD/CD-TFT 1 Intellectual Property Rights and National Development Goals – Ensuring Innovation in Russia St. Petersburg/Moscow Study Tour 2008 Christoph.
FEASIBILITY OF NATIONAL DISCLOSURE OF ORIGIN REQUIREMENTS 21 April 2005 WTO Symposium, Geneva Disclosure Requirements: Incorporating the CBD Principles.
© 2008 International Intellectual Property June 22, 2009 Class 6 Patents: Multilateral Agreements (Paris Convention); Economics of International Patent.
WIPO – Ono Academic College – Israel Ministry of Foreign Affairs Traditional Knowledge The Open Questions Dr. Shlomit Yanisky-Ravid Shalom Comparative.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
Unit 3 Lesson 5 Technology Transfer and Patents. Big Idea Patents are catalysts of new technologies and businesses and they stimulate economic development.
Implementing the WIPO Development Agenda: Comparing National Approaches to Promoting Coherence Between Public Policy Objectives and IP Laws ICTSD Roundtable.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Intellectual Property Rights and Pharmaceuticals (Following Up the ‘Novartis case’ ) Background note prepared for PHM Vic Internet Workshop.
© A. Kur IP in Transition – Proposals for Amendment of TRIPS Annette Kur, MPI Munich.
A: Copy –Rights – Artistic, Literary work, Computer software Etc. B: Related Rights – Performers, Phonogram Producers, Broadcasters etc. C: Industrial.
LEGAL ASPECTS OF DIGITAL LIBRARIES By TALWANT SINGH ADDL DISTT. & SESSIONS JUDGE; DELHI.
Overview of Issues and Interests in Standards and Interoperability Mary Saunders Chief, Standards Services Division NIST.
“PERUVIAN EXPERIENCE IN THE PROTECTION OF TRADITIONAL KNOWLEDGE” Presentation by Minister Counsellor Betty Berendson, Deputy Permanent Representative of.
Consideration Towards Development of Intellectual Property System Dr. Li Yuguang Deputy Commissioner the State Intellectual Property Office of P. R. China.
CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur TRIPS – Article.
IP Offices and the Implementation of the WIPO Development Agenda: Challenges and Opportunities September 18, 2009 Geneva Irfan Baloch World Intellectual.
Biosafety and Bioethical issues
Biotechnology / Life Sciences Ensuring Access Christina Sampogna July 2005 CASRIP – University of Washington, Seattle *Views expressed are those of the.
Session 9: Cross-Cutting Issues. Law and Policy of Relevance to the Management of Plant Genetic Resources  To describe the key cross-cutting.
NATIONAL CONFERENCE Intellectual Property Policies for Universities and Innovation dr. sc. Vlatka Petrović Head, Technology Transfer Office Acting Head,
Why an Intellectual Property Policy? Sofia, November 24 and 25, 2015 Mr. Evgeniy Sesitsky, Department for Transition and Developed Countries, World Intellectual.
© 2004 The IPR-Helpdesk is a project of the European Commission DG Enterprise, co-financed within the fifth framework programme of the European Community.
Selected Contemporary Issues in Field of Patents WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
Intellectual Property Law Introduction Victor H. Bouganim WCL, American University.
Regulatory Administrative Institutions MPA 517 Lecture-7 1.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Law and Policy of Relevance for the Management of Plant Genetic Resources Objectives of Session 6 To discuss the meaning of sui generis protection.
Basic Principles: Ethics and Business
INTELECTUAL PROPERTY RIGHTS
Designing a Dynamic IP System in the Republic of Belarus
Exception to rules on free trade
Susy Frankel Victoria University of Wellington New Zealand
Introduction Intellectual property includes the application of property in the areas of trade secrets, patents, trademarks, and copyrights.
National Contact Points (NCP) Training
44 Nursing: A Concept-Based Approach to Learning Ethics MODULE
IP Protection under the WTO
Sub-Regional Meeting for ASEAN Countries on the Marrakesh Treaty and the Production and Exchange of Accessible Books by the World Intellectual Property.
The Global Landscape of IP/TK
EBS Law Term 2016 Intellectual Property Law Fields and Principles
WIPO – Ono Academic College – Israel Ministry of Foreign Affairs
Presentation transcript:

WIPO: Life Sciences symposium: IP and Bioethics A framework for looking at IP and Bioethics September 2007 A.S.Taubman Global IP Issues Division, WIPO

bioethics? as against ethics, moral issues writ large? – what is distinctive about life sciences? is it about outcomes? – a moral judgement as to right and wrong? – who decides, and on what basis? is it about a way of making policy choices? – consultation, consent, a broader framework? is it a judgement on behaviour? – what kinds of research activities, ways of doing business do we favour?

IP and bioethics: law or ethics? IP systems largely a creature of statute – Law vs. ethics: what is ethical aspect of lawmaking guided by public policy? – Ethically neutral? Or policy space for ethical considerations? – Law vs. morality: question of patentability of morally questionable technologies Natural rights basis for [some] IP laws and principles – Article 15.1(c) ICESCR, Art 27.2 UDHR but strong utilitarian flavour to IP law and policy, increasingly emphasized in current debate on IP as a tool of public policy – Article 7, TRIPS

distinguish… ethical aspects of a technology as such ethical aspects of national authorities granting IP ethical aspects of an individual seeking exclusive IP ethical aspects of the forms of exercising IP rights

distinguish… ethical aspects of a technology as such – e.g. the ethics of stem cell research ethical aspects of national authorities granting IP ethical aspects of an individual seeking exclusive IP ethical aspects of the forms of exercising IP rights

distinguish… ethical aspects of a technology as such ethical aspects of national authorities granting IP – e.g. ethics of a patent office granting patents on life forms ethical aspects of an individual seeking exclusive IP ethical aspects of the forms of exercising IP rights

distinguish… ethical aspects of a technology as such ethical aspects of national authorities granting IP ethical aspects of an individual seeking exclusive IP – e.g. ethics of a public funded agency patenting research) ethical aspects of the forms of exercising IP rights

distinguish… ethical aspects of a technology as such ethical aspects of national authorities granting IP ethical aspects of an individual seeking exclusive IP ethical aspects of the forms of exercising IP rights – e.g. ethics of licensing patents key medical technologies).

distinguish… ethical aspects of a technology as such – e.g. the ethics of stem cell research ethical aspects of national authorities granting IP – e.g. ethics of a patent office granting patents on life forms ethical aspects of an individual seeking exclusive IP – e.g. ethics of a public funded agency patenting research) ethical aspects of the forms of exercising IP rights – e.g. ethics of licensing patents key medical technologies).

?

Some distinctions Ethics and IP law and practice – In the sense of guidance for right behaviour – e.g. When is consent regarding seeking IP an ethical question? Morality and IP law and practice – In the sense of determining innate right & wrong – e.g. substantive references to morality in IP laws Exclude patent protection for technologies the exploitation of which would be contrary to morality Trademarks contrary to morality Moral rights in copyright and related rights

International law: States may exclude from protection inventions on morality grounds (Article 27.2, WTO TRIPS Agreement). States agree to leave space for morality considerations to apply at the domestic level: – They then have the option to create a specific morality exception within their own national patent laws. – In exercising such an exception, a decision maker working within the national system may be required to undertake a specific ethical judgment about a particular technology.

distinguish… ethical aspects of a technology as such – e.g. the ethics of stem cell research ethical aspects of national authorities granting IP – e.g. ethics of a patent office granting patents on life forms ethical aspects of an individual seeking exclusive IP – e.g. ethics of a public funded agency patenting research) ethical aspects of the forms of exercising IP rights – e.g. ethics of licensing patents key medical technologies).

the BRCA gene patent

IP and bioethics: some themes Transparency Consent Benefit sharing Crossover between law and morality Accommodating different value systems

Transparency in the patent system Transparency as the basis for ethical scrutiny of relevant technologies Patent information systems used to monitor: trends and background in key technologies state of the art in key technologies research and patenting activities of firms/institutes/individuals But need for improved use/access of patent information, and value-added information products to guide policymaking

International patent applications on human, animal or plant cell lines by year of publication (Source: Patentscope)

Source: Wikimedia Commons. Permission is granted to copy, distribute and/or modify this document under the terms of the GNU Free Documentation License, Version 1.2 or any later version published by the Free Software Foundation; with no Invariant Sections, no Front- Cover Texts, and no Back-Cover Texts. A copy of the license is included in the section entitled "GNU Free Documentation License".this documentGNU Free Documentation LicenseFree Software FoundationGNU Free Documentation License

NOVEL BIODEGRADABLE AGRICULTURAL AND PHARMACEUTICAL FORMULATIONS BASED ON COW URINE, NEEM AND OTHER HERBS, EFFECTIVE AS PEST REPELLENT, PLANT IMMUNO-STIMULANT, PLANT GROWTH PROMOTING AND ANTI-FUNGAL AGENT. Application 1104/MUM/2002 published , filed A process for production of sustained release formulation based on active fraction of cow urine with herbs which is useful as pest repellant, plant immunostimulant and plant growth promoting agent is described. The characteristic features are:- 1) There is a combination of fraction of cow urine with extracts of some active herbs. 2) Dried mixture is palletized with the help of suitable binders. 3) The pellets are coated with suitable polymers to controlled/desired release rate. 4) The product is biodegradable, ecofriendly and polyfunctional. Applicant DORLE AVINASH KESHAV & 16 OTHERS 42, RAMNAGAR, PIROJSHANAGAR, NAGPUR: , MAHARASHTRA, INDIA. Inventor AS ABOVE. International Info Classification:

United States Patent 6,410,059 Khanuja, et al. June 25, 2002 Pharmaceutical composition containing cow urine distillate and an antibiotic A pharmaceutical composition comprising an antibiotic and cow urine distillate in an amount effective to enhance antimicrobial effect of the antibiotic is disclosed. The antibiotic can be an antifungal agent. The antibiotic can be a quinolone or a fluoroquinolone. The antifungal agent can be azoles, clotrimazole, mystatin or amphotericin. Inventors: Khanuja; Suman Preet Singh (Lucknow, IN), Kumar; Sushil (Lucknow, IN), Shasany; Ajit Kumar (Lucknow, IN), Arya; Jai Shankar (Lucknow, IN), Darokar; Mahendra Pandurang (Lucknow, IN), Singh; Monika (Lucknow, IN), Sinha; Prachi (Lucknow, IN), Awasthi; Soumya (Lucknow, IN), Gupta; Subhash Chandra (Lucknow, IN), Gupta; Vivek Kumar (Lucknow, IN), Gupta; Madan Mohan (Lucknow, IN), Verma; Ram Kishore (Lucknow, IN), Agarwal; Sweta (Lucknow, IN), Mansinghka; Sunil Balkrishna (Nagpur, IN), Dawle; Suresh Haribhau (Nagpur, IN) Assignee: Council of Scientific and Industrial Research (New Delhi, IN) Citations: U.S May 2001 Schiller, Japan May2000

Traditional chinese medicine

inclusion and consultation NGO accreditation to the IGC Where accredited organizations are active 1 organization 2 to 5 organizations more than 5 organizations

Traditional knowledge and IP indigenous peoples have rarely placed anything in the so called public domain, a term without meaning to us... the public domain is a construct of the IP system and does not take into account domains established by customary indigenous laws - Saami Council

misuse of TK can cause severe physical or spiritual harm to the individual caretakers of the knowledge or their entire tribe from their failure to ensure that the Creators gifts were properly used, even if misuse was used by others outside of the tribe, or by tribal members who were outside of the control of customary authority. For this reason... misappropriation and misuse [is] not simply a violation of moral rights leading to a collective offense, but a matter of cultural survival for many indigenous peoples. – Tulalip Tribes Traditional knowledge and IP

IP and the sharing of benefits UNBHR: equitable access to medical, scientific and technological developments as well as the greatest possible flow and the rapid sharing of knowledge concerning those developments and the sharing of benefits, with particular attention to the needs of developing countries;

IP in research agreements UNBHR: When negotiating a research agreement, terms for collaboration and agreement on the benefits of research should be established with equal participation by those party to the negotiation. (art 21.4)

IP and bioethics in the innovation process research policy and planning the research phase the acquisition of IP rights the use of new technology, and exercise IP of rights

Ideally: each stage guided by an overarching conception of workable, equitable and effective arrangements for innovation in the public interest, consistent with legitimate private interests -- the ethical basis of good public policymaking? reviewing IP and bioethics issues throughout the technology development pipeline

a concluding example many have called for an open source approach to biotechnology what are the bioethics-IP implications?

should protection of IP should contribute to the promotion of technological innovation and to the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare, and to a balance of rights and obligations. WTO TRIPS Agreement, art. 7

but what is the nature of that should? should - as – ethical (deontological), – ethical (utilitarian), – legal (obligatory) – aspirational, or – predictive? within legal text, guide to broader interpretation within policy context, guide to policymaker – an heuristic?

what message to life science policymakers? if one should encourage or adopt open source innovation in the life sciences – prudential – it is good for you, it serves your objective interests; – ethical: any right thinking person would do so; – social utilitarian: – it yields overall welfare outcomes; – legal – you must do it, whether or not it is in your real or perceived interests. Each has been made for open source approaches to life sciences innovation. How does the nature of the should depend on who and where you are?

two layers of should essence of IP policymaking is setting what legally defined exclusivities over knowledge resources will advance innovation, fair competition and public welfare, and how those exclusivities should be shaped and governed. – some open source ideas hard-wired at the legislative level (or can be) individual holders of exclusive rights are also presented with a range of obligations – ethical and legal - and motivations. – when and how is there a convergence of the overall architecture of the IP system, the interests and behaviour of players within that system, and the kinds of modes characterized as open source in the life sciences?

some approaches to IP and bioethics… bioethics within the law of patents: the scope for judgements about morality in assessments on patentability bioethics considerations in consultations on policymaking bioethics as a guide to practice in medical research and in business bioethics and fundamental rights and responsibilities